TCRCure Biopharma Corp is a world-class, “One-Stop Shop” cell therapy operation built across the U.S. and China. We deliver the latest cell therapy advances directly to patients with solid tumors. As of 2021, we have treated more than 50 patients and built more than a dozen CAR-T/TCR-T pipelines. TCRCure’s cutting-edge platform technologies include antigen-specific TCR/CAR discovery, immune-cell engineering, and industry-scale viral vector production. We operate 40,000 sq. ft. of specialized facilities on both sides of the Pacific, including scalable GMP capacity for cell production and viral manufacturing. TCRCure works closely with world-class hospitals in China and the United States for clinical research in different solid tumors. Current indications including cervical cancer, ovarian cancer, nasopharyngeal carcinoma, lung squamous carcinoma, melanoma, sarcoma, endometrial cancer, and brain cancer.
Employees: 51-200
Founded date: 2016